The HCC recurrence rate among untreated patients was 40% at 1 year, 70% at two years, and 90% at 4 years and was higher than the rates among patients treated with IFN-α (25% at 1 year, 30% at two years, and 47% at four years). The gene discussed is IFNA2; the disease is hepatocellular carcinoma.